TITLE

Antidiabetic Effect of Essential Oil from Artemisia sieberi Growing in Jordan in Normal and Alloxan Induced Diabetic Rats

AUTHOR(S)
Irshaid, F.; Mansi, K.; Aburjai, T.
PUB. DATE
May 2010
SOURCE
Pakistan Journal of Biological Sciences;2010, Vol. 13 Issue 9, p423
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The aim of this study was to evaluate the effects of essential oil extracted from aerial parts of Artemisia sieberi in normal and alloxan induced diabetic rats. Fifty rats were divided into five groups of 10 each. Group I normal rats received 1 mL day-1 of dimethyl sulfoxide (control); group II normal rats received a single dose (80 mg kg-1 b.wt.) of essential oil extract of Artemisia sieberi; group III diabetic rats received 1 mL day-1 of dimethyl sulfoxide; group IV diabetic rats received the oil extract (80 mg kg-1 b.wt.); group V diabetic rats received metformin (14.2 mg kg-1 b.wt.). All treatments were orally administered once a day for six weeks. Changes in blood glucose concentration, body weight and food and water intake were measured and the data obtained were compared with that of metformin. The essential oil extract significantly (p<0.05) lowered blood glucose level as well as food and water intake in diabetic rats accompanied by an increase in body weight gam with no apparent side effect when compared with untreated diabetic rats. These effects were found to be closely similar to that of metformin, a common antidiabetic drug. On other hand, no apparent improvement on body weight gam in diabetic rats treated with metformin. In addition, for all parameters measured, the oil extract showed no effect in normal rats. In conclusion, the essential oil of Artemisia sieberi exhibited antidiabetic activity in alloxan-induced diabetic rats. Present findings support the possible use of the essential oil of Artemisia sieberi as a remedy for diabetes mellitus in humans.
ACCESSION #
52868417

 

Related Articles

  • Older diabetes drugs produced similar glycemic effects as new drugs. Kalvaitis, Katie // Cardiology Today;Jan2008, Vol. 11 Issue 1, p14 

    The article discusses research being done on the glycemic effects of old diabetes drugs. It references a study by Shari Bolen and colleagues, published in "Annals of Internal Medicine." Researchers reviewed different oral diabetes drugs including thiazolidinediones (TZD), metformin and...

  • Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study. Lund, Søren Søgaard; Tarnow, Lise; Astrup, Anne Sofie; Hovind, Peter; Jacobsen, Peter Karl; Alibegovic, Amra Ciric; Parving, Ida; Pietraszek, Lotte; Frandsen, Merete; Rossing, Peter; Parving, Hans-Henrik; Vaag, Allan Arthur // PLoS Clinical Trials;Oct2008, Vol. 5 Issue 10, Special section p1 

    Background: Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type- 2 diabetes. We investigated the effect of a one-year treatment...

  • Meta-analysis finds antidiabetic drugs lower glucose similarly when added to metformin in type 2 diabetes mellitus.  // Formulary;May2010, Vol. 45 Issue 5, p146 

    The article discusses research into the efficacy of noninsulin antidiabetic drugs in lowering blood glucose in patients with type 2 diabetes mellitus. Clinicians have called into question the diabetes treatment guidelines from the American Diabetes Association and the European Association for...

  • Antihyperglycemic and Antioxidant Properties of Jaceosidin, a Flavonoid Isolated from Artemisia Princeps, in Type 2 Diabetic Mice. Young-Jin Kang; Un-Ju Jung; Seon-Min Jeon; Ji-Young Yeo; Hye-Jin Kim; Dong-Ju Kim; Mi-Kyoung Lee; Nam-In Baek; Hae-Gon Chung; Myung-Sook Choi // Diabetes;Jun2007 Supplement 1, Vol. 56, pA667 

    Flavonoids have been identified as the antidiabetic components in a number of traditional ethnic remedies. However, the mechanisms whereby these compounds exert their hypoglycemic and antioxidant action in type 2 diabetes have rarely been investigated. Therefore, this study investigated the...

  • Metformin does not harm diabetic patients with heart failure.  // Journal of Family Practice;Dec2007, Vol. 56 Issue 12, p996 

    The article focuses on the risk of oral hypoglycemics to patients with diabetes and heart failure. It is stated that some evidence suggests the control of blood glucose to be associated with worse outcomes in patients with heart failure. It is noted that antidiabetic agents such as metformin may...

  • Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy. Hettihewa, L. M.; Jayasinghe, S. S.; Imendra, K. G.; Weerarathna, T. P. // International Journal of Diabetes in Developing Countries;Jan-Mar2008, Vol. 28 Issue 1, p26 

    OBJECTIVE: To examine effects of pioglitazone (PIO) on systolic, diastolic, pulse and mean blood pressures (SBP, DBP, PP and MP, respectively) in type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: One hundred and six normotensive patients with T2DM with mean fasting blood glucose (FBS; 183...

  • Exenatide: A New Promising Antidiabetic Agent. CHAKRABORTI, C. K. // Indian Journal of Pharmaceutical Sciences;Jan/Feb2010, Vol. 72 Issue 1, p1 

    Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay...

  • Impact of LX4211 on Cardiovascular Risk Factors in Type 2 Diabetes. Vinall, Phil // MD Conference Express;Dec2012, p26 

    The article discusses the results from the Safety and Efficacy of LX4211 with Metformin in T2DM Patients with Inadequate Glycemic Control on Metformin study by Julio Rosenstock. The study evaluates the dose-range efficacy and safety of LX4211 versus placebo from baseline to Week 12 in patients,...

  • Effect of antihyperglycaemic agents added to metformin and a sulfonylurea in type 2 diabetes.  // Australian Journal of Pharmacy;Nov2011, Vol. 92 Issue 1098, p90 

    The article examines the effect of adding a third antihyperglycaemic drug (AHD) to the ongoing metformin and sulfonylurea medication, when blood glucose control is not achieved in patients with type 2 diabetes. Results of studies conducted to evaluate the effect of AHD on glycemic control and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics